MGMT immunoreactivity and promoter methylation status were significantly associated in renal cell carcinoma (p<0.05), breast carcinoma (p<0.05) and lung carcinoma (p<0.025). A similar trend was seen i

NIAID Data Ecosystem80

Artificial neural network identified a 20-gene panel with promising value in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in GBM patients

GBM胶质母细胞瘤

肿瘤生物标志物

Question: Which biomarker can effectively predict the immunotherapy response and prognostic benefits of GBM patients, and how can potential responders to immune checkpoint inhibitors (ICIs) be disc

Figshare2021-02-25 更新40

BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers. BRCAness, SLFN11 and RB1 loss predict response to topoisomerase I inhibitors in triple negative breast cancers

乳腺癌药物反应

肿瘤生物标志物

Expression data from patient-derived xenografts of human triple-negative breast cancers Overall design: We used GeneChip Human 1.1 ST arrays to identify the genes differentially expressed in PDX with

NIAID Data Ecosystem20

MGMT immunoreactivity and promoter methylation status in the individual tumor subgroups of brain metastases.

资源简介：

MGMT immunoreactivity and promoter methylation status in the individual tumor subgroups of brain metastases.

资源简介：

相关数据集